Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Bibliographic Details
Main Authors:	Coates, L, Wallman, J, McGonagle, D, Schett, G, McInnes, I, Mease, P, Rasouliyan, L, Quebe-Fehling, E, Asquith, D, Fasth, A, Pricop, L, Gaillez, C
Format:	Journal article
Published:	BioMed Central 2019

Similar Items

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
by: Laura C. Coates, et al.
Published: (2019-12-01)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
by: Orbai, A-M, et al.
Published: (2019)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
by: Pournara, E, et al.
Published: (2021)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
by: A. Deodhar, et al.
Published: (2019-05-01)

Effects of TNF-α inhibition secukinumab on active ultrasound-confirmed enthesitis in psoriatic arthritis
by: Ashley Elliott, et al.
Published: (2023-11-01)

SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS
by: E. E. Gubar, et al.
Published: (2018-11-01)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
by: Coates, L, et al.
Published: (2018)

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study
by: Coates, L, et al.
Published: (2020)

Enthesitis in psoriatic arthritis
by: Mihaela Agache, et al.
Published: (2021-09-01)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
by: Dennis McGonagle, et al.
Published: (2023-04-01)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
by: Philip J. Mease, et al.
Published: (2023-08-01)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
by: L. C. Coates, et al.
Published: (2018-12-01)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
by: Peter Nash, et al.
Published: (2018-03-01)

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
by: Coates, L, et al.
Published: (2018)

Enthesitis in psoriatic arthritis – is the clinical evaluation enough?
by: Daniela-Raluca Decianu, et al.
Published: (2020-09-01)

Long term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease
by: Reich, K, et al.
Published: (2019)

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
by: Iain B McInnes, et al.
Published: (2022-03-01)

ENTHESITIS AND PSORIATIC ONYCHOPATHY AS A FACTOR FOR PREDICTION OF PSORIATIC ARTHRITIS IN PSORIASIS
by: Tatyana G. Sidorcika, et al.
Published: (2018-04-01)

CLINICALLY EVIDENT ENTHESITIS OCCURS FREQUENTLY IN PSORIATIC ARTHRITIS, BUT IS NOT ASSOCIATED WITH DISEASE SEVERITY
by: Williamson, L, et al.
Published: (2003)

Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison
by: Philip Mease, et al.
Published: (2019-07-01)

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
by: Philip Mease, et al.
Published: (2022-12-01)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
by: Baraliakos, X, et al.
Published: (2022)

Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2020-07-01)

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
by: Renaud Felten, et al.
Published: (2023-10-01)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01)

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis
by: Reich, K, et al.
Published: (2022)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
by: Coates, LC, et al.
Published: (2023)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
by: Alice B. Gottlieb, et al.
Published: (2022-04-01)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
by: Strand, V, et al.
Published: (2022)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
by: Sara Alonso, et al.
Published: (2021-05-01)

Considerations for the definition of remission criteria in psoriatic arthritis
by: Mease, P, et al.
Published: (2017)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
by: Laure Gossec, et al.
Published: (2022-07-01)

Enthesitis is a clue to the diagnosis of spondyloarthritis, focus on psoriatic arthritis
by: Ye. D. Yehudina, et al.
Published: (2021-02-01)

The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
by: Ari Polachek, et al.
Published: (2017-08-01)

Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial
by: Baraliakos, X, et al.
Published: (2021)

Secukinumab treatment in psoriatic patients: Italian experiences
by: Luca Idolazzi
Published: (2018-11-01)

Secukinumab in multi-failure psoriatic patients: the last hope?
by: M. Magnano, et al.
Published: (2018-08-01)

Tofacitinib Blocks Entheseal Lymphocyte Activation and Modulates MSC Adipogenesis, but Does Not Directly Affect Chondro- and Osteogenesis
by: Tobias Russell, et al.
Published: (2021-12-01)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
by: Mease, P, et al.
Published: (2017)